| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | sta1 |
| Uniprot No | P01559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 55-72aa |
| 氨基酸序列 | NTFYCCELCCNPACAGCY |
| 预测分子量 | 28.6 kDa |
| 蛋白标签 | GST tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STA1重组蛋白的参考文献示例(注：文献为假设示例，建议通过学术数据库核实最新研究)：
---
1. **"Cloning and Expression of STA1 Gene Encoding a Glucoamylase in Saccharomyces cerevisiae"**
*Author: Yamamoto, K. et al.*
**摘要**: 研究报道了酿酒酵母中STA1基因的克隆及其重组葡糖淀粉酶的表达，分析了该酶在淀粉底物水解中的活性，并探讨了其在工业发酵中的应用潜力。
2. **"Heterologous Production and Characterization of Thermophilic STA1 α-Amylase in E. coli"**
*Author: Zhang, L. et al.*
**摘要**: 通过大肠杆菌异源表达嗜热菌来源的STA1重组α-淀粉酶，纯化后证实其高温稳定性(最适温度75℃)，并解析了其在食品加工中的高效催化特性。
3. **"Structural Insights into STA1 Recombinant Protein from Streptomyces hygroscopicus"**
*Author: Patel, R. & Kim, S.*
**摘要**: 利用X射线晶体学解析了链霉菌STA1重组蛋白的三维结构，揭示了其底物结合口袋的独特构象，为理性改造酶活性提供依据。
4. **"Functional Analysis of STA1 Recombinant Protein in Fungal Pathogenicity"**
*Author: Chen, X. et al.*
**摘要**: 研究在毕赤酵母中表达病原真菌的STA1重组蛋白，证实其通过降解植物细胞壁多糖增强宿主侵染能力，为抗真菌靶点开发奠定基础。
---
建议通过 **PubMed、Web of Science** 或 **Google Scholar** 检索关键词“STA1 recombinant protein”或“STA1 gene expression”获取真实文献。
Sta1 (Staphylococcal toxin 1) recombinant protein is a genetically engineered protein derived from *Staphylococcus aureus*, a Gram-positive bacterium notorious for causing infections ranging from skin abscesses to life-threatening sepsis. Sta1 belongs to the superantigen family, a class of virulence factors that disrupt immune responses by non-specifically activating T-cells, leading to excessive cytokine release and systemic inflammation. Unlike conventional antigens, superantigens bypass normal antigen processing, binding directly to MHC class II molecules on antigen-presenting cells and T-cell receptors, triggering a disproportionate immune response.
The recombinant Sta1 protein is typically produced using bacterial or mammalian expression systems, enabling controlled study of its structure-function relationships without the risks associated with handling live pathogens. Its crystal structure reveals conserved domains critical for receptor binding and toxin activity, including a characteristic β-barrel fold and hydrophobic regions involved in cell membrane interactions. Research on Sta1 focuses on understanding its role in pathogenesis, particularly in toxic shock syndrome and antibiotic-resistant infections like methicillin-resistant *S. aureus* (MRSA).
Clinically, recombinant Sta1 serves as a tool for developing diagnostics, therapeutics, and vaccines. Neutralizing antibodies against Sta1 have shown promise in preclinical models, while epitope-mapping studies aim to design targeted inhibitors. Additionally, engineered attenuated variants are explored as vaccine candidates to induce protective immunity. Despite progress, challenges remain in balancing immunogenicity and safety in therapeutic applications. Ongoing studies also investigate Sta1's potential as a biomarker for severe staphylococcal infections, underscoring its dual role as both a therapeutic target and a research reagent in combating *S. aureus*-related diseases.
×
